Literature DB >> 2379537

Nonlinear kinetics of propafenone metabolites in healthy man.

S Vozeh1, W Haefeli, H R Ha, J Vlcek, F Follath.   

Abstract

The pharmacokinetics of oral and i.v. propafenone and its major metabolites have been investigated in 8 healthy subjects. The total body clearance of propafenone was 963 ml/min, the terminal half-life 198 min and its absolute bioavailability was 15.5%. The two active metabolites (5-hydroxypropafenone and N-depropylpropafenone) showed non-linear kinetics in that both the dose-corrected area under the serum concentration-time curve and the amount excreted in the urine were larger after oral dosing. This resulted in considerably higher serum concentrations of the metabolites despite comparable serum concentrations of the parent compound. Thus, the concentration-effect relationship in the same patient may differ after oral and intravenous doses if concentrations of the active metabolite(s) are not taken into consideration. Although the mechanism of the nonlinearity is not clear, the data indicate that it may be due to saturable biliary excretion of the metabolites.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2379537     DOI: 10.1007/bf02336693

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  13 in total

1.  The statistical sign test.

Authors:  W J DIXON; A M MOOD
Journal:  J Am Stat Assoc       Date:  1946-12       Impact factor: 5.033

Review 2.  A review of metabolite kinetics.

Authors:  K S Pang
Journal:  J Pharmacokinet Biopharm       Date:  1985-12

Review 3.  Drug metabolites in renal failure: pharmacokinetic and clinical implications.

Authors:  R K Verbeeck; R A Branch; G R Wilkinson
Journal:  Clin Pharmacokinet       Date:  1981 Sep-Oct       Impact factor: 6.447

4.  The metabolic fate of 2H-labelled propafenone in man.

Authors:  H G Hege; M Hollmann; S Kaumeier; H Lietz
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1984 Jan-Mar       Impact factor: 2.441

5.  Metabolite cumulation during chronic propafenone dosing in arrhythmia.

Authors:  R E Kates; Y G Yee; R A Winkle
Journal:  Clin Pharmacol Ther       Date:  1985-06       Impact factor: 6.875

6.  A controlled trial of propafenone for treatment of frequent and repetitive ventricular premature complexes.

Authors:  D M Salerno; G Granrud; P Sharkey; R Asinger; M Hodges
Journal:  Am J Cardiol       Date:  1984-01-01       Impact factor: 2.778

7.  Pharmacological studies on propafenone and its main metabolite 5-hydroxypropafenone.

Authors:  G von Philipsborn; J Gries; H P Hofmann; H Kreiskott; R Kretzschmar; C D Müller; M Raschack; H J Teschendorf
Journal:  Arzneimittelforschung       Date:  1984

8.  Propafenone disposition kinetics in cardiac arrhythmia.

Authors:  S Connolly; C Lebsack; R A Winkle; D C Harrison; R E Kates
Journal:  Clin Pharmacol Ther       Date:  1984-08       Impact factor: 6.875

9.  Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences.

Authors:  L A Siddoway; K A Thompson; C B McAllister; T Wang; G R Wilkinson; D M Roden; R L Woosley
Journal:  Circulation       Date:  1987-04       Impact factor: 29.690

10.  European experience with the antiarrhythmic efficacy of propafenone for supraventricular and ventricular arrhythmias.

Authors:  P Coumel; J F Leclercq; P Assayag
Journal:  Am J Cardiol       Date:  1984-11-14       Impact factor: 2.778

View more
  6 in total

1.  LG 6-101 and LG 6-102, two new propafenone-related antiarrhythmic agents with good oral activity in rats.

Authors:  T C Wascher; P Dittrich; W R Kukovetz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-04       Impact factor: 3.000

2.  Pharmacokinetics of CYP2C9, CYP2C19, and CYP2D6 substrates in healthy Chinese and European subjects.

Authors:  Sijie Lu; R A Nand; J S Yang; Gang Chen; A S Gross
Journal:  Eur J Clin Pharmacol       Date:  2017-11-27       Impact factor: 2.953

3.  Identification of propafenone metaboliser phenotype from plasma and urine excretion data.

Authors:  R Latini; M Belloni; R Bernasconi; E Cappiello; P Giani; M Landolina; D Leopaldi; J M Castel
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 4.  Propafenone. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in cardiac arrhythmias.

Authors:  H M Bryson; K J Palmer; H D Langtry; A Fitton
Journal:  Drugs       Date:  1993-01       Impact factor: 9.546

5.  Stereoselective steady state disposition and action of propafenone in Chinese subjects.

Authors:  G Li; P L Gong; J Qiu; F D Zeng; U Klotz
Journal:  Br J Clin Pharmacol       Date:  1998-11       Impact factor: 4.335

Review 6.  Clinical pharmacokinetics of propafenone.

Authors:  J T Hii; H J Duff; E D Burgess
Journal:  Clin Pharmacokinet       Date:  1991-07       Impact factor: 6.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.